Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Stuart Rich, MD has served as our Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. |
| 2022-04-28 | Stuart Rich, MD, has served as our Chief Medical Officer since January 2021 and a director since February 2021. Our Board of Directors believes that Dr. Rich’s extensive medical background in the field of pulmonary hypertension and experience as a consultant and standing member of the Cardiovascular and Renal Advisory Committee of the U.S. Food and Drug Administration qualify him to serve on our Board. Dr. Rich's total compensation for 2021 was $818,315. |
| 2023-04-28 | Stuart Rich, MD has served as our Chief Medical Officer since January 2021 and a director since February 2021. ... Our Board of Directors believes that Dr. Rich’s extensive medical background in the field of pulmonary hypertension and experience as a consultant and standing member of the Cardiovascular and Renal Advisory Committee of the U.S. Food and Drug Administration qualify him to serve on our Board. |
| 2023-10-27 | Stuart Rich, MD 216,554 * |
| 2024-04-26 | Stuart Rich, MD has served as our Chief Medical Officer since January 2021 and a director since February 2021. Our Board of Directors believes that Dr. Rich’s extensive medical background in the field of pulmonary hypertension and experience as a consultant and standing member of the Cardiovascular and Renal Advisory Committee of the U.S. Food and Drug Administration qualify him to serve on our Board. |
Data sourced from SEC filings. Last updated: 2025-07-01